MYB and breast carcinoma: Our observation that fulvestrant, which is in clinical use for breast cancer treatment, appears to substitute in this regard for MYB knockdown suggests that the combination of this agent with clinically acceptable DIAs might be one approach to bring this approach to clinical application.